Will the current coronavirus situation affect biotech and pharma business development?Yes...and No. As with most things, the answer depends on your point of view, the market you happen to be in,…
Are virtual or digital partnering conferences the wave of the future? Or will we revert back to face to face conferences once the current crisis is over?We are conducting a…
It is an interesting question. With so much information and mis-information coming at us, it is difficult to tackle this issue in a meaningful and insightful way. For those of you who are statistically…
Ophthalmology is changing. If we look back 5-10 years, topical formulations of novel or established drugs were the norm in ophthalmology product development. These days, we are seeing antisense, gene…
Happy New Year, everybody. And with the new year comes the annual report from the FDA/CDER on novel drug approvals. CDER approve8 48 novel candidates in 2019, down from the 59 approvals…
Which stories were the most interesting in 2019? And, what should we look forward to in 2020?In this video, we answer these questions. This is the third or fourth year…
Biopharma Dive recently published a series of articles on biotech bankruptcies. The first lists bankruptcies in 2019, while the other lists companies which are teetering towards bankruptcy. As the article notes,…
Like you, we go to a lot of partnering conferences...BIO...BIO-Europe...BioTrinity...and so on. But these conferences are expensive, time consuming, and exhausting. So...how can we get the most value from these…
A few months ago, the Centers for Disease Control published a new analysis, concluding that the US is experiencing "a steep, sustained increases in sexually transmitted diseases." The CDC has a…
Remember me?Back in the mid-80s, when the Sony Walkman was a cassette player, companies like Upjohn, Parke-Davis, and Schering-Plough were well known in the pharmaceutical community. These names, and many others,…